News Sentiment

ARCT sentiment intelligence

Arcturus Therapeutics Holdings Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.97 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-4.3% over one week, +0.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -4.3% Price reacting lower
Trend fit Trend inactive 0.0% over four weeks
Fair value -62.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 40
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 11
TradingView 6
simplywall.st 6
TradingKey 5
Moomoo 3
Kavout | AI 2
Intellectia AI 1

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 22
Analyst action 6
Regulatory and legal 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
Stock Titan Direct company coverage

Board member at Arcturus (NASDAQ: ARCT) receives 15,000 stock options

Arcturus Therapeutics Holdings Inc. director Magda Marquet was granted 15,000 stock options with an exercise price of $7.30 per share, expiring on June 5, 2036. These options vest monthly over one year and represent her 2026 annual grant as a Board member. The transaction indicat

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 02:09
Source
Stock Titan
Stock Titan Direct company coverage

Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 grant

Arcturus Therapeutics Holdings Inc. director Edward W. Holmes received a grant of 15,000 stock options as part of his 2026 annual board compensation. The options allow him to buy common stock at an exercise price of $7.30 per share and expire on June 5, 2036. These options will v

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Arcturus (ARCT) director Jing L. Marantz granted 15,000 stock options

Arcturus Therapeutics Holdings Inc. director Jing L. Marantz was granted 15,000 stock options at an exercise price of $7.30 per share, expiring on June 5, 2036. This grant represents her 2026 annual compensation for Board service, with the options vesting monthly over one year fr

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Director Peter Farrell receives 15,000 Arcturus (NASDAQ: ARCT) stock options

Arcturus Therapeutics Holdings Inc. director Peter C. Farrell has been granted 15,000 stock options as part of his 2026 annual compensation for Board service. The options have an exercise price of $7.3000 per share, expire on June 5, 2036, and will vest monthly over one year from

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Director at Arcturus (NASDAQ: ARCT) receives 15,000 stock options grant

Arcturus Therapeutics Inc. director James F. Barlow was granted 15,000 stock options as part of his 2026 board compensation. These options allow him to buy common stock at an exercise price of $7.30 per share and will vest monthly over a one-year period, aligning his compensation

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 21:09
Source
Stock Titan
TradingView Direct company coverage

Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies

Arcturus Therapeutics presented its mRNA pipeline, including vaccine approvals and clinical milestones, at the Jefferies Global Healthcare Conference. The company emphasized its differentiated LUNAR delivery platform and manufacturing capabilities for therapeutic mRNA application

Tone
Positive 75/100
Event
Market update
Published
05 Jun 2026 23:39
Source
TradingView